Analyst firms · Oppenheimer · MRNA
Oppenheimer MRNA price target and rating history
Moderna Inc. (MRNA) · Health Care
Oppenheimer rates Moderna Inc. (MRNA) Perform with a $142 price target, as of its latest action on Sep 13, 2024. It has published 3 rating actions on MRNA since August 2021, including 1 upgrade and 2 downgrades. Across 6 firms with a MRNA price target in the last 12 months, the median target is $57.
- Current rating
- Perform
- Price target
- $142
- Median target, all firms
- $57
- Actions on MRNA
- 3
Every Oppenheimer rating on MRNA
- Sep 13, 2024
- Jan 2, 2024
- Aug 6, 2021
How other firms rate MRNA
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| William Blair | Mkt Perform | Oct 27, 2026 | |
| Citigroup | Sell | $80 | Sep 30, 2026 |
| Rothschild & Co Redburn | Sell | $81 | Sep 3, 2026 |
| Argus Research | Buy | $180 | Aug 28, 2026 |
| Wolfe Research | Peer Perform | Aug 25, 2026 | |
| BofA Securities | Neutral | Aug 19, 2026 | |
| Barclays | Equal Weight | $25 | Jan 28, 2026 |
| UBS | Neutral | $34 | Jan 7, 2026 |
| Jefferies | Hold | $30 | Dec 12, 2025 |
Questions about Oppenheimer and MRNA
- What is Oppenheimer's price target for MRNA?
- Oppenheimer's latest stated price target for Moderna Inc. (MRNA) is $142, from its action on Jan 2, 2024.
- What is Oppenheimer's rating on MRNA?
- Oppenheimer rates MRNA Perform, a neutral rating, as of Sep 13, 2024.
- When did Oppenheimer last change its view on MRNA?
- On Sep 13, 2024, Oppenheimer downgrades to Perform from Outperform.
- How does Oppenheimer's MRNA target compare with other analysts?
- Across 6 firms with a MRNA price target in the last 12 months, the median target is $57.
More MRNA rating histories
- William Blair3
- Argus Research3
- Wolfe Research3
- BofA Securities3
- Barclays4
- UBS3
- Jefferies5
- HSBC5
- Deutsche Bank7
- TD Cowen4
- Leerink Partners5
- Morgan Stanley5
- Piper Sandler3
All Oppenheimer ratingsMRNA news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.